InspireMD, Inc.

InspireMD, Inc. announced it will release its second quarter financial results on Monday, August 17, 2026. Following the release, the company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and recent highlights. Interested parties can register online to receive dial-in details, and a webcast will be available on the company's investor relations website.

InspireMD, Inc. has appointed Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. Ms. Kennedy brings over 30 years of medical device sales leadership experience, including significant expertise in carotid intervention and carotid stenting. Her return to InspireMD, where she previously led regional sales for the CGuard Prime U.S. launch, is expected to be invaluable for the anticipated U.S. commercialization and relaunch of the CGuard platform.

InspireMD, Inc. announced that the position of Chief Commercial Officer has been eliminated. Shane Gleason, who held the role, was informed of this change on July 23, 2026. His final day of employment with the company is scheduled for July 31, 2026.

InspireMD, Inc. received a notice from Nasdaq on July 17, 2026, indicating non-compliance with the minimum bid price requirement for continued listing. The company's common stock traded below $1.00 for 30 consecutive business days. InspireMD has been granted a 180-calendar-day period, until January 13, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The company is evaluating options, including a reverse stock split, to address the deficiency.

InspireMD announced the resignation of Raymond W. Cohen from its Board of Directors, effective July 1, 2026. Mr. Cohen, a Class III director and member of both the Audit and Compensation Committees, cited personal considerations for his departure. The company stated that his resignation was not due to any disagreement with InspireMD, its Board, or management. The Nominating and Corporate Governance Committee plans to identify suitable candidates to fill the vacant position.

InspireMD, Inc. announced that its Compensation Committee approved inducement grants of 91,161 restricted shares to six new non-executive employees. These grants, made under the 2024 Inducement Plan, are intended to incentivize the new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock vests over a three-year period, with one-third vesting on the first anniversary and the remainder in two equal installments on the second and third anniversaries, subject to continued employment.

InspireMD announced positive 30-day outcomes from its CGUARDIANS II clinical trial for the CGuard Prime 80 cm implant, intended for transcarotid artery revascularization (TCAR) procedures. The trial demonstrated 100% acute device success with no deaths, strokes, myocardial infarctions, or stent thrombosis reported within 30 days. A Premarket Approval (PMA) supplement is currently under FDA review, with potential approval in the second half of 2026, which could significantly expand the company's addressable market to include TCAR procedures.

InspireMD announced the enrollment of the first patient in its CGUARDIANS III pivotal study for the SwitchGuard neuro protection system (NPS). This study evaluates the safety and efficacy of SwitchGuard NPS, used with the CGuard Prime 80 cm stent platform, in transcarotid artery revascularization (TCAR) procedures. The company aims to capture a share of the estimated 70,000 TCAR procedures expected annually in the U.S. by 2030, with the SwitchGuard NPS potentially setting a new standard of care.

InspireMD, Inc. held its 2026 annual meeting of stockholders, where an amendment to the Company's Amended and Restated Certificate of Incorporation was approved. This amendment increases the authorized number of common stock shares from 150,000,000 to 250,000,000. Additionally, stockholders re-elected Marvin Slosman, Raymond Cohen, and Dan Dearen to the board of directors and ratified Kesselman & Kesselman as the independent registered public accounting firm for the 2026 fiscal year.

InspireMD, Inc. announced that Mr. Paul Stuka will not seek re-election as a Class I director and plans to retire from the Board of Directors at the Company's 2027 Annual Meeting of Stockholders. Mr. Stuka currently serves as the Chair of the Board and the Compensation Committee, and is a member of the Audit and Nominating and Corporate Governance Committees. His decision was not due to any disagreement with the company, and he is expected to continue serving until his term expires. The Nominating and Corporate Governance Committee will identify suitable candidates for the Board as part of succession planning.